10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

OR

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to          

NORTECH SYSTEMS INCORPORATED

Commission file number 0-13257

State of Incorporation: Minnesota

IRS Employer Identification No. 41-1681094

Executive Offices: 7550 Meridian Circle N., Suite # 150, Maple Grove, MN 55369

Telephone number: (952) 345-2244

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	NSYS	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐	Accelerated Filer ☐
Non-accelerated Filer ☒	Smaller Reporting Company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐    

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒

Number of shares of $.01 par value common stock outstanding at August 5, 2022 was 2,683,513.

1

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

				PAGE
	Item 1	-	Financial Statements
			Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	3
			Condensed Consolidated Balance Sheets	4
			Condensed Consolidated Statements of Cash Flows	5
			Condensed Consolidated Statements of Shareholders’ Equity	6
			Condensed Notes to Consolidated Financial Statements	7-17
	Item 2	-	Management's Discussion and Analysis of Financial Condition And Results of Operations	18-25
	Item 3	-	Quantitative and Qualitative Disclosures About Market Risk	26
	Item 4	-	Controls and Procedures	26
PART II - OTHER INFORMATION
	Item 1	-	Legal Proceedings	27
	Item 1A.	-	Risk Factors	27
	Item 2	-	Unregistered Sales of Equity Securities, Use of Proceeds	27
	Item 3	-	Defaults on Senior Securities	27
	Item 4	-	Mine Safety Disclosures	27
	Item 5	-	Other Information	27
	Item 6	-	Exhibits	28
SIGNATURES				29

2

PART

ITEM 1. FINANCIAL STATEMENTS

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(IN THOUSANDS, EXCEPT SHARE DATA)

	THREE MONTHS ENDED						SIX MONTHS ENDED
	JUNE 30,						JUNE 30,
	2022			2021			2022			2021
Net Sales	$	32,518		$	30,182		$	63,229		$	52,254
Cost of Goods Sold		27,514			26,597			54,181			47,108
Gross Profit		5,004			3,585			9,048			5,146
Operating Expenses
Selling Expenses		960			571			1,793			1,292
General and Administrative Expenses		2,668			2,418			5,397			5,214
Research and Development Expenses		351			207			679			207
Restructuring Charges		-			77			-			296
Gain on Sale of Assets		-			(94	)		(15	)		(94	)
Total Operating Expenses		3,979			3,179			7,854			6,915
Income (Loss) From Operations		1,025			406			1,194			(1,769	)
Other Expense
Interest Expense		(117	)		(116	)		(215	)		(202	)
Income (Loss) Before Income Taxes		908			290			979			(1,971	)
Income Tax Expense (Benefit)		189			111			122			(596	)
Net Income (Loss)	$	719		$	179		$	857		$	(1,375	)
Net Income (Loss) Per Common Share:
Basic (in dollars per share)	$	0.27		$	0.07		$	0.32		$	(0.52	)
Weighted Average Number of Common Shares Outstanding - Basic (in shares)		2,683,131			2,658,926			2,681,931			2,659,028
Diluted (in dollars per share)	$	0.25		$	0.06		$	0.30		$	(0.52	)
Weighted Average Number of Common Shares Outstanding - Diluted (in shares)		2,886,755			2,767,991			2,879,216			2,659,028
Other comprehensive (loss) income
Foreign currency translation		(244	)		58			(239	)		24
Comprehensive income (loss), net of tax	$	475		$	237		$	618		$	(1,351	)

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

3

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS 

(IN THOUSANDS, EXCEPT SHARE DATA)

	JUNE 30			DECEMBER 31,
	2022			2021(1)
	(Unaudited)
ASSETS
Current Assets
Cash	$	944		$	643
Restricted Cash		231			1,582
Accounts Receivable, less allowances of $297 and $328		16,468			14,548
Employee Retention Credit Receivable		5,209			5,209
Inventories, Net		22,970			19,434
Contract Assets		9,070			8,698
Prepaid Expenses and Other Current Assets		1,563			1,660
Total Current Assets		56,455			51,774
Property and Equipment, Net		6,144			5,833
Operating Lease Assets		8,420			8,983
Other Intangible Assets, Net		471			501
Total Assets	$	71,490		$	67,091
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Current Portion of Finance Lease Obligations	$	447		$	601
Current Portion of Operating Lease Obligations		1,099			1,043
Accounts Payable		14,108			12,710
Accrued Payroll and Commissions		3,961			4,045
Other Accrued Liabilities		4,675			3,907
Total Current Liabilities		24,290			22,306
Long-Term Liabilities
Long Term Line of Credit		11,360			8,959
Long Term Finance Lease Obligations, Net		734			916
Long-Term Operating Lease Obligations, Net		8,103			8,695
Other Long-Term Liabilities		100			104
Total Long-Term Liabilities		20,297			18,674
Total Liabilities		44,587			40,980
Commitments and Contingencies
Shareholders' Equity
Preferred Stock, $1 par value; 1,000,000 Shares Authorized: 250,000 Shares Issued and Outstanding		250			250
Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,683,513 and 2,672,064 Shares Issued and Outstanding, respectively		27			27
Additional Paid-In Capital		16,136			15,962
Accumulated Other Comprehensive (Income) Loss		(183	)		56
Retained Earnings		10,673			9,816
Total Shareholders' Equity		26,903			26,111
Total Liabilities and Shareholders' Equity	$	71,490		$	67,091

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

⁽¹⁾ The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited financial statements at that date

4

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)

	SIX MONTHS ENDED
	JUNE 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$	857		$	(1,375	)
Adjustments to Reconcile Net Income (Loss) to Net Cash
Provided By (Used In) Operating Activities:
Depreciation and Amortization		967			967
Compensation on Stock-Based Awards		141			160
Change in Accounts Receivable Allowance		(31	)		116
Change in Inventory Reserves		(103	)		(655	)
Gain on Sale of Assets		(15	)		(94	)
Changes in Current Operating Items
Accounts Receivable		(1,986	)		(1,153	)
Inventories		(3,540	)		(3,719	)
Contract Assets		(372	)		(1,019	)
Prepaid Expenses and other Curent Assets		89			(286	)
Income Taxes		(63	)		(757	)
Accounts Payable		1,346			1,576
Accrued Payroll and Commissions		(84	)		686
Other Accrued Liabilities		854			120
Net Cash Used In Operating Activities		(1,940	)		(5,433	)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from Sale of Property and Equipment		15			94
Purchase of Intangible Asset		(41	)		(77	)
Purchases of Property and Equipment		(1,182	)		(659	)
Net Cash Used In Investing Activities		(1,208	)		(642	)
CASH FLOWS FROM FINANCING ACTIVITIES
Net Change in Line of Credit		2,394			4,339
Principal Payments on Long-Term Debt		-			(249	)
Principal Payments on Financing Leases		(336	)		(326	)
Debt Issuance Costs		7			-
Stock Option Excercises		33			-
Net Cash Provided By Financing Activities		2,098			3,764
Net Change in Cash and Cash Equivalents		(1,050	)		(2,311	)
Cash and Cash Equivalents - Beginning of Period		2,225			3,564
Cash and Cash Equivalents - End of Period	$	1,175		$	1,253
Reconciliation of cash and restricted cash reported within the consolidated balance sheets
Cash	$	944		$	661
Restricted Cash		231			592
Total Cash and restricted cash reported in the consolidated statements of cash flows	$	1,175		$	1,253
Supplemental Disclosure of Cash Flow Information:
Cash Paid During the Period for Interest	$	198		$	81
Cash Paid During the Period for Income Taxes		20			156
Supplemental Noncash Investing and Financing Activities:
Property and Equipment Purchases in Accounts Payable		52			-
Property Acquired Under Operating Lease		-			858

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

5

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(UNAUDITED)

(IN THOUSANDS)

							Accumulated
					Additional		Other						Total
	Preferred		Common		Paid-In		Comprehensive			Retained			Shareholders'
	Stock		Stock		Capital		Loss			Earnings			Equity
BALANCE MARCH 31, 2021	$	250	$	27	$	15,837	$	(71	)	$	1,108		$	17,151
Net Income		-		-		-		-			179			179
Foreign currency translation adjustment		-		-		-		58			-			58
Compensation on stock-based awards		-		-		25		-			-			25
BALANCE JUNE 30, 2021	$	250	$	27	$	15,862	$	(13	)	$	1,287		$	17,413
BALANCE DECEMBER 31, 2020	$	250	$	27	$	15,816	$	(37	)	$	2,662		$	18,718
Net Loss		-		-		-		-			(1,375	)		(1,375	)
Foreign currency translation adjustment		-		-		-		24			-			24
Compensation on stock-based awards		-		-		46		-			-			46
BALANCE JUNE 30, 2021	$	250	$	27	$	15,862	$	(13	)	$	1,287		$	17,413
BALANCE MARCH 31, 2022	$	250	$	27	$	16,043	$	61		$	9,954		$	26,335
Net Income		-		-		-		-			719			719
Foreign currency translation adjustment		-		-		-		(244	)		-			(244	)
Compensation on stock-based awards		-		-		93		-			-			93
BALANCE JUNE 30, 2022	$	250	$	27	$	16,136	$	(183	)	$	10,673		$	26,903
BALANCE DECEMBER 31, 2021	$	250	$	27	$	15,962	$	56		$	9,816		$	26,111
Net Income		-		-		-		-			857			857
Foreign currency translation adjustment		-		-		-		(239	)		-			(239	)
Stock option exercises		-		-		33		-			-			33
Compensation on stock-based awards		-		-		141		-			-			141
BALANCE JUNE 30, 2022	$	250	$	27	$	16,136	$	(183	)	$	10,673		$	26,903

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

6

CONDENSED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(UNAUDITED)

NOTE 1.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements, although we believe the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other interim period. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these condensed consolidated financial statements, we have made our best estimates and judgments of certain amounts included in the condensed consolidated financial statements, giving due consideration to materiality. Changes in the estimates and assumptions used by us could have a significant impact on our financial results, since actual results could differ from those estimates.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Revenue Recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation. Revenue is recorded net of returns, allowances and customer discounts. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs charged to our customers are included in net sales, while the corresponding shipping expenses are included in cost of goods sold.

7

 

Stock-Based Awards

Stock Options

In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of 350,000 shares. An additional 50,000 and 175,000 shares were authorized by the shareholders in March 2020 and May 2022, respectively.

We granted 0 and 21,000 market condition options to our Chief Executive Officer during the three and six months ended June 30, 2022, respectively. The market condition options vest if certain stock prices are exceeded between February 27, 2024 and February 27, 2028. We granted 13,000 and 66,000 service-based options during the three and six months ended June 30, 2022, respectively. Total option grants for the three and six months ended June 30, 2022 were 13,000 and 108,000, respectively. There were 3,000 stock options granted during the six months ended June 30, 2021.

Total compensation expense related to stock options was $64 and $106 for the three and six months ended June 30, 2022, respectively. Total compensation expense related to stock options was $25 and $46 for the three and six months ended June 30, 2021. As of June 30, 2022, there was $851 of unrecognized compensation which will vest over the next 3.90 years.

Following is the status of all stock options as of June 30, 2022:

	Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding - January 1, 2022		387,500		$	4.57
Granted		87,000			11.10
Exercised		(12,000	)		3.41
Cancelled		(4,400	)		3.36
Outstanding - June 30, 2022		458,100		$	5.82		6.97	$	3,326
Exercisable - June 30, 2022		222,700		$	3.93		6.12	$	2,038

Restricted Stock Units

During the three and six months ended June 30, 2022, we granted 3,000 and 21,000 restricted stock units (“RSUs”), respectively, under our 2017 Stock Incentive Plan to non-employee directors which vest over two years. There were no RSUs outstanding prior to the six months ended June 30, 2022. Total compensation expense related to the RSUs were $29 and $35 for the three and six months ended June 30, 2022, respectively. There was no compensation expense related to RSUs for the three and six months ended June 30, 2021. Total unrecognized compensation expense related to the RSUs was $218, which will vest over the next 1.74 years. The RSUs granted in the six months ended June 30, 2022 had an average grant price of $12.00 per share with a weighted average remaining contractual term of 9.73 years. No RSUs vested during the six months ended June 30, 2022.

8

 

Equity Appreciation Rights Plan

In November 2010, the Board of Directors adopted the Nortech Systems Incorporated Equity Appreciation Rights Plan (“2010 Plan”). The total number of Equity Appreciation Right Units (“Units”) that can be issued under the 2010 Plan shall not exceed an aggregate of 1,000,000 Units as amended and restated on March 11, 2015. There were no units granted during the six months ended June 30, 2022 or June 30, 2021.

The 100,000 units outstanding at December 31, 2021 were paid on March 29, 2022. As of June 30, 2022, there are no units outstanding. Total compensation expense related to the vested outstanding Units based on the estimated appreciation over their remaining terms was $100 and $114 for the three and six months ended June 30, 2021, respectively.

Net Income (Loss) per Common Share

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Dilutive net income (loss) per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding, unless their effect is antidilutive. All stock options and restricted stock units, while outstanding, are considered common stock equivalents.

For the three and six months ended June 30, 2022, stock options of 203,625 and 197,285, respectively were included in the computation of diluted net income per common share as their impact were dilutive. For the three months ended June 30, 2021, stock options of 109,065 were included in the computation of diluted net income per common share. For the six months ended June 30, 2021, all stock options are deemed to be antidilutive and therefore, were not included in the computation of net income per common share amount.

We had outstanding stock options totaling 45,878 and RSUs totaling 19,114 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the three months ended June 30, 2022. We had average outstanding stock options totaling 48,895 and RSUs totaling 20,057 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the six months ended June 30, 2022. Outstanding stock options totaling 622 are not considered in the computation of diluted net income per share for the three months ended June 30, 2021.

Restricted Cash

Cash and cash equivalents classified as restricted cash on our consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. As of June 30, 2022 we had outstanding letters of credit for $400. Restricted cash as of June 30, 2022 was $231. The June 30, 2022 restricted cash balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

Accounts Receivable and Allowance for Doubtful Accounts

Credit is extended based upon an evaluation of the customer’s financial condition and, while collateral is not required, the Company periodically receives surety bonds that guarantee payment. Credit terms are consistent with industry standards and practices. Trade accounts receivable have been reduced by an allowance for doubtful accounts of $297 at June 30, 2022 and $328 at December 31, 2021.

9

 

Inventories

Inventories are stated at the lower of average cost (which approximates first-in, first out) or net realizable value. Costs include material, labor, and overhead required in the warehousing and production of our products. Inventory reserves are maintained for the estimated value of the inventories that may have a lower value than stated or quantities in excess of future production needs.

Inventories are as follows:

	June 30,			December 31,
	2022			2021
Raw Materials	$	21,764		$	18,492
Work in Process		1,793			1,678
Finished Goods		608			562
Reserves		(1,195	)		(1,298	)
Total	$	22,970		$	19,434

Other Intangible Assets

Other intangible assets at June 30, 2022 and December 31, 2021 are as follows:

	Customer Relationships		Trade Names		Patents		Total
Balance at January 1, 2021	$	507	$	589	$	77	$	1,173
Additions		-		-		64		64
Amortization		147		29		-		176
Abandonment Loss		-		560		-		560
Balance at December 31, 2021		360		-		141		501
Additions		-		-		41		41
Amortization		71		-		-		71
Balance at June 30, 2022	$	289	$	-	$	182	$	471

Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted-average remaining amortization period of our in-use intangible asset is 2.0 years. Patents are not being amortized as they are in process and a patent has not yet been received.

Amortization expense of finite life intangible assets for the three and six months ended June 30, 2022 was $35 and $71, respectively. Amortization expense for the three and six months ended June 30, 2021 was $46 and $92, respectively.

10

 

Estimated future annual amortization expense (not including the patents in process) related to these assets is approximately as follows:

Year	Amount
Remainder of 2022	$	72
2023		145
2024		72
Total	$	289

Accounting Pronouncements Issued But Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The ASU also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities that meet the definition of a Smaller Reporting Company as defined by the SEC for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.

NOTE 2.   CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. With regard to cash, we maintain our excess cash balances in checking accounts at primarily two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. Of the $1,175 in cash and restricted cash at June 30, 2022, approximately $691 and $54 was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and do not require collateral on our accounts receivable.

We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances individually represented 10% or more of total accounts receivable. One customer accounted for 28% and 26% of net sales for the three and six months ended June 30, 2022, respectively. One customer accounted for 25% and 27% of net sales for the three and six months ended June 30, 2021, respectively.

At June 30, 2022, two customers represented approximately 37% of our total accounts receivable. At December 31, 2021, one customer represented approximately 19% of our total accounts receivable.

Export sales represented approximately 4% of net sales for both the three and six months ended June 30, 2022. Export sales represented approximately 2% and 3% of net sales for the three and six months ended June 30, 2021 respectively.

11

NOTE 3.   REVENUE

Revenue recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct.

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 74% of our revenue for both the three and six months ended June 30, 2022 and 82% and 79% of our revenue for the three and six months ended June 30, 2021, respectively. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred.

Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.

On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.

12

 

Contract Assets

Contract assets, recorded as such in the Condensed Consolidated Balance Sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the six months ended June 30, 2022 was as follows (in thousands):

Balance outstanding at December 31, 2021	$	8,698
Increase (decrease) attributed to:
Transferred to receivables from beginning contract assets		(8,360	)
Product transferred over time to ending contract assets		8,732
Balance outstanding at June 30, 2022	$	9,070

We expect substantially all the remaining performance obligations for the contract assets recorded as of June 30, 2022 to be transferred to receivables within 90 days, with the majority of any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

The following tables summarize our net sales by market:

	Three Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	13,165	$	4,763	$	610	$	18,538
Industrial		6,930		2,196		328		9,454
Aerospace and Defense		3,989		336		201		4,526
Total net sales	$	24,084	$	7,295	$	1,139	$	32,518

	Three Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	12,776	$	3,050	$	244	$	16,070
Industrial		8,287		1,738		151		10,176
Aerospace and Defense		3,738		122		76		3,936
Total net sales	$	24,801	$	4,910	$	471	$	30,182

13

 

	Six Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	22,972	$	9,678	$	1,154	$	33,804
Industrial		13,459		3,987		675		18,121
Aerospace and Defense		10,046		761		497		11,304
Total net sales	$	46,477	$	14,426	$	2,326	$	63,229

	Six Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	21,735	$	5,942	$	734	$	28,411
Industrial		12,917		3,075		403		16,395
Aerospace and Defense		6,802		384		262		7,448
Total net sales	$	41,454	$	9,401	$	1,399	$	52,254

NOTE 4.   FINANCING ARRANGEMENTS

We have a credit agreement with Bank of America which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16,000 that expires on June 15, 2026.

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 3.9% and 3.5% as of June 30, 2022 and December 31, 2021, respectively. We had borrowings on our line of credit of $11,410 and $9,016 outstanding as of June 30, 2022 and December 31, 2021, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $50 and $58 on the consolidated balance sheet for the periods ended June 30, 2022 and December 31, 2021, respectively.

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0 for the twelve months ended at each Fiscal Quarter end subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 days. As of June 30, 2022 the Company was in compliance with its covenants.

At June 30, 2022, we had unused availability under our line of credit of $4,190 supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability.

14

NOTE 5.   LEASES

We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. At June 30, 2022, we do not have material lease commitments that have not commenced.

The components of lease expense were as follows:

	Three Months Ended June 30,		Three Months Ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	578	$	589
Finance lease interest cost		17		21
Finance lease amortization expense		183		163
Total lease cost	$	778	$	773

	Six Months Ended June 30,		Six Months ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	1,159	$	1,120
Finance lease interest cost		36		43
Finance lease amortization expense		365		326
Total lease cost	$	1,560	$	1,489

Supplemental balance sheet information related to leases was as follows:

	Balance Sheet Location	June 30, 2022		December 31, 2021
Assets
Operating lease assets	Operating lease assets	$	8,420	$	8,983
Finance lease assets	Property, plant and equipment		1,867		2,052
Total leased assets		$	10,287	$	11,035

Supplemental cash flow information related to leases was as follows:

	June 30,		June 30,
	2022		2021
Operating leases
Cash paid for amounts included in the measurement of lease liabilities	$	862	$	821
Right-of-use assets obtained in exchange for lease obligations	$	-	$	858

15

 

Maturities of lease liabilities were as follows:

	Operating Leases			Finance Leases			Total
Remaining 2022	$	871		$	293		$	1,164
2023		1,789			409			2,198
2024		1,507			357			1,864
2025		1,255			103			1,358
2026		1,217			115			1,332
Thereafter		7,066			-			7,066
Total lease payments	$	13,705		$	1,277		$	14,982
Less: Interest		(4,504	)		(96	)		(4,600	)
Present value of lease liabilities	$	9,201		$	1,181		$	10,382

The lease term and discount rate at June 30, 2022 were as follows:

Weighted-average remaining lease term (years)
Operating leases	9.2
Finance leases	2.6
Weighted-average discount rate
Operating leases	7.7	%
Finance leases	5.2	%

NOTE 6.   INCOME TAXES

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction.

Our effective tax rate for the three and six months ended June 30, 2022 was 21% and 12%, respectively. The effective tax rate for the three and six months ended June 30, 2021 was 38% and 30%, respectively. The primary driver of the change in the effective tax rate is attributable to a US loss compared to income from the foreign entities.

NOTE 7.   RESTRUCTURING CHARGES

During the first six months of 2021, we recorded restructuring charges of $296 related to the consolidation of our production facilities and closure of our Merrifield, Minnesota facility. We had a gain on sale of assets of $15 and $94 in the six months ended June 30, 2022 and 2021, respectively, related to the sale of machinery and equipment. There were no restructuring charges or amounts accrued in the six months ended June 30, 2022.

16

NOTE 8.   EMPLOYEE RETENTION CREDIT

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law providing numerous tax provisions and other stimulus measures, including an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERC.

At June 30, 2022 and December 31, 2021, the Company has ERC benefits of $5,209 within Employee Retention Credits Receivable on the condensed consolidated balance sheet.

NOTE 9.   RELATED PARTY TRANSACTIONS

David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. Mr. Kunin also was a consultant to Abilitech, which relationship ended on March 1, 2021. In the three and six months ended June 30, 2022, Abilitech paid the Company $163 and $217, respectively, for delivery of medical products. In the three and six months ended June 30, 2021, Abilitech paid the Company $472 and $740, respectively for the delivery of medical products. The Company believes that transactions with Abilitech are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated third party.

David Kunin, our Chairman, is a minority owner (less than 10%) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $1,000 conditional grant. The Company and Marpe Technologies will each receive $500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $500 to match grant funds from the BIRD Foundation. The Company will meet its obligation by providing certain services at cost or no cost to Marpe Technologies. The total value of the contribution will not exceed $500; the Company has contributed $182 as of June 30, 2022. The Company will receive a 10-year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recoup the value of services provided to Marpe for which is not fully paid. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the six months ended June 30, 2022, we recognized revenue of $113. There was no revenue recognized for the six months ended June 30, 2021. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party.

17

ITEM 2.       MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We are a Minnesota, United States based full-service global EMS contract manufacturer in the Medical, Aerospace & Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our products are complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit board assemblies, higher-level assemblies, and other box builds for a wide range of industries. We serve three major markets within the EMS industry: Aerospace and Defense, Medical, and the Industrial market which includes industrial capital equipment, transportation, vision, agriculture, oil and gas. We maintain facilities in Bemidji, Blue Earth, Mankato, and Milaca, Minnesota; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.

Recent Developments

Global Pandemic

The COVID-19 pandemic continued to impact our business in the first six months of 2022, primarily by continued supply chain disruptions and delays. The full extent to which COVID-19 will directly or indirectly impact our business, financial condition, and results of operations will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.

We will continue to assess the current and potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations. We actively manage our cash and working capital to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times.

18

Results of Operations

The following table presents statements of operations data as percentages of total net sales for the periods indicated:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2022			2021			2022			2021
Net Sales		100.0	%		100.0	%		100.0	%		100.0
Cost of Goods Sold		84.6			88.1			85.7			90.1
Gross Profit		15.4			11.9			14.3			9.9
Selling Expenses		2.9			1.9			2.8			2.5
General and Administrative Expenses		8.2			8.0			8.5			10.0
R&D Expenses		1.1			0.7			1.1			0.4
Restructuring Charges		-			0.3			-			0.6
Gain on Sale of Property and Equipment		0.0			(0.3	)		0.0			(0.2	)
Income (Loss) from Operations		3.2			1.3			1.9			(3.4	)
Interest Expense		(0.4	)		(0.3	)		(0.3	)		(0.4	)
Income (Loss) Before Income Taxes		2.8			1.0			1.6			(3.8	)
Income Tax Expense (Benefit)		0.6			0.4			0.2			(1.2	)
Net (Loss) Income		2.2	%		0.6	%		1.4	%		(2.6	)%

Net Sales

Net sales for the three months ended June 30, 2022 and 2021 were $32.5 and $30.2 million, respectively, an increase of $2.3 million or 8%. Net sales for the six months ended June 30, 2022 and 2021 were $63.2 million and $52.3 million, respectively, an increase of $11.0 million or 21.0%. The three and six month increases were driven by increased demand as well as price increases to counteract higher material and labor cost. We have also taken actions to scale the direct labor workforce and strengthen the supply chain for parts.

Net sales to medical and defense customers increased compared to prior year for both the three and six month periods ended June 30, 2022. Sales to industrial customers decreased in the three months ended June 30, 2022 versus the same period in the prior year primarily due to supply chain challenges for electronic components.

19

Net sales by our major EMS industry markets for the three and six months ended June 30, 2022 and 2021 were as follows (in millions):

	Three Months Ended June 30,							Six Months Ended June 30,
	2022		2021		% Change			2022		2021		% Change
Medical	$	18.9	$	16.1		17.4		$	33.8	$	28.4		19.0
Industrial		9.4		10.2		(7.8	)		18.1		16.4		10.4
Aerospace and Defense		4.2		3.9		7.7			11.3		7.5		50.7
Total Net Sales	$	32.5	$	30.2		7.6		$	63.2	$	52.3		20.8

Net sales by timing of transfer of goods and services for the three and six months ended June 30, 2022 is as follows (in millions):

	Three Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	13.2	$	4.8	$	0.6	$	18.6
Industrial		6.9		2.2		0.3		9.4
Aerospace and Defense		3.9		0.4		0.2		4.5
Total net sales		24.0		7.4		1.1		32.5

	Six Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	23.0	$	9.7	$	1.1	$	33.8
Industrial		13.4		4.0		0.7		18.1
Aerospace and Defense		10.0		0.8		0.5		11.3
Total net sales	$	46.4	$	14.5	$	2.3	$	63.2

20

Net sales by timing of transfer of goods and services for the three and six months ended June 30, 2021 is as follows (in millions):

	Three Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	12.8	$	3.1	$	0.2	$	16.1
Industrial		8.3		1.7		0.2		10.2
Aerospace and Defense		3.7		0.1		0.1		3.9
Total net sales	$	24.8	$	4.9	$	0.5	$	30.2

	Six Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	21.7	$	6.0	$	0.7	$	28.4
Industrial		12.9		3.1		0.4		16.4
Aerospace and Defense		6.8		0.4		0.3		7.5
Total net sales	$	41.4	$	9.5	$	1.4	$	52.3

21

Backlog

Our 90-day shipment backlog as of June 30, 2022 was $35.9 million, a 1.2% increase from the beginning of the quarter and a 3.5% increase from June 30, 2021. Our backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be transferred within 180 days.

Our 90-day shipment backlog by market has remained relatively constant when compared to the prior quarter end and the same period of the prior year. 90-day shipment backlog by our major industry markets are as follows (in millions):

	Shipment Backlog as of the Period Ended
	June 30		March 31		June 30
	2022		2022		2021
Medical	$	20.9	$	19.7	$	18.9
Industrial		9.8		9.7		9.8
Aerospace and Defense		5.2		6.0		6.0
Total 90-Day Backlog	$	35.9	$	35.4	$	34.7

Our 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next. Our total shipment backlog was $106.2 million and $71.5 million as of June 30, 2022 and 2021, respectively. This backlog contains the contract asset value of $9.1 million which have been recognized as revenue.

Gross Profit

Gross profit as a percent of net sales was 15.4% and 11.9% for the three months ended June 30, 2022 and 2021, respectively. Gross profit as a percent of net sales was 14.3% and 9.9% for the six months ended June 30, 2022 and 2021, respectively. The gross profit improvement was primarily driven by price increases in response to material and labor cost inflation as well as higher production volume which increased plant utilization.

Selling Expense

Selling expenses for the three months ended June 30, 2022 and 2021 were $1.0 million or 2.9% of sales and $0.6 million or 1.9% of sales, respectively. Selling expenses for the six months ended June 30, 2022 and 2021 were $1.8 million or 2.8% of sales and $1.3 million or 2.5% of sales, respectively. The increase in selling expense for the three and six months ended June 30, 2022 compared to the same periods of the prior year relates to an increase in headcount to support the increased sales.

General and Administrative Expense

General and administrative expenses for the three months ended June 30, 2022 and 2021 were $2.7 million or 8.2% of sales and $2.4 million or 8.0% of sales, respectively. General and administrative expenses for the six months ended June 30, 2022 and 2021 were $5.4 million or 8.5% of sales and $5.2 million or 10.0% of sales, respectively. General and administrative expenses for the three and six months ended June 30, 2022 were held relatively flat compared to the same periods of the prior year, and are generally fixed in nature.

22

Restructuring Charges

Restructuring charges for the three and six months ended June 30, 2021 were $0.1 million and $0.3 million, respectively. There were no restructuring charges for the three and six months ended June 30, 2022. The restructuring charges relate to the closure of the Merrifield facility during 2021.

Research and Development Expense

Research and development expenses were $0.4 million or 1.1% of net sales for the three months ended June 30, 2022 and $0.7 million or 1.1% of net sales for the six months ended June 30, 2022. Research and development expenses for both the three and six months ended June 30, 2021 was $0.2 million.

Income (Loss) From Operations

Income from operations for the three months ended June 30, 2022 was $1.0 million compared to $0.4 million for the three months ended June 30, 2021. Income from operations for the six months ended June 30, 2022 was $1.2 million compared to a loss from operations of $1.8 million for the six months ended June 30, 2021. The three and six month improvements compared to the same periods of the prior year were driven by the increase in sales and gross margin as a percent of sales.

Interest Expense

Interest expense was $0.1 million for both the three months ended June 30, 2022 and 2021. Interest expense was $0.2 million for both the six months ended June 30, 2022 and 2021.

Income Taxes

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction.

Our effective tax rate for the three and six months ended June 30, 2022 was 21% and 12%, respectively. The effective tax rate for the three and six months ended June 30, 2021 was 38% and 30%, respectively. The primary driver of the change in the effective tax rate is attributable to a US loss compared to income from the foreign entities.

Net Income (Loss)

Net income for the three months ended June 30, 2022 was $719 thousand or $0.27 per basic common share and $0.25 per diluted common share. Net income for the three months ended June 30, 2021 was $179 thousand or $0.07 per basic common share and $0.06 per diluted common share. Net income for the six months ended June 30, 2022 was $857 thousand or $0.32 per basic common share and $0.30 per diluted common share. Net loss for the six months ended June 30, 2021 was ($1,375) thousand or ($0.52) per basic and diluted common share.

Liquidity and Capital Resources

We believe that our existing financing arrangements, anticipated cash flows from operations, funds expected to be received for the ERC and cash on hand will be sufficient to satisfy our working capital needs for the next twelve months, capital expenditures and debt repayments.

23

Credit Facility

We have a credit agreement with Bank of America which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16.0 million that expires on June 15, 2026.

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 3.9% and 3.5% as of June 30, 2022 and December 31, 2021, respectively. We had borrowings on our line of credit of $11.4 million and $9.0 million outstanding as of June 30, 2022 and December 31, 2021, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $50 thousand and $58 thousand on the consolidated balance sheet for the periods ended June 30, 2022 and December 31, 2021, respectively.

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0 for the twelve months ended at each Fiscal Quarter end subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 days. As of June 30, 2022 the Company was in compliance with its covenants.

At June 30, 2022, we had unused availability under our line of credit of $4.2 million supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability.

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.

24

Forward-Looking Statements

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

♦	Volatility in the marketplace which may affect market supply, demand of our products, labor rates or currency exchange rates;
♦	Supply chain disruption and unreliability;
♦	Lack of supply of sufficient human resources to produce our products;
♦	Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;
♦	Changes in the reliability and efficiency of our operating facilities or those of third parties;
♦	Increases in certain raw material costs such as copper and oil;
♦	Commodity and energy cost instability;
♦	Risks related to FDA noncompliance;
♦	The loss of a major customer;
♦	General economic, financial and business conditions that could affect our financial condition and results of operations;
♦	Increased or unanticipated costs related to compliance with securities and environmental regulation;
♦	Disruption of global or local information management systems due to natural disaster or cyber-security incident;
♦	Outbreaks of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers' operations or our suppliers' operations.

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Discussion of these factors is also incorporated in Part I, Item 1A, “Risk Factors,” and should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-K are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

25

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

26

PART II

ITEM 1. LEGAL PROCEEDINGS

We are subject to various legal proceedings and claims that arise in the ordinary course of business.

ITEM 1A. RISK FACTORS

We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading “Part I – Item 1A.Risk Factors.” There have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2021.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

As of June 30, 2022, our share repurchase program has expired, and no additional amounts are available for repurchase.

ITEM 3. DEFAULTS ON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

27

ITEM 6. EXHIBITS

Exhibits

31.1*	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
31.2*	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
32*	Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	Financial statements from the quarterly report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Condensed Notes to Condensed Consolidated Financial Statements.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith

28

Signatures

-------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nortech Systems Incorporated and Subsidiaries

--------------------------------------------------------

Date: August 9, 2022	by /s/ Jay D. Miller
	Jay D. Miller
	Chief Executive Officer and President
	Nortech Systems Incorporated
Date: August 9, 2022	by /s/ Christopher D. Jones
	Christopher D. Jones
	Vice President and Chief Financial Officer
	Nortech Systems Incorporated

29

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Jay D. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Nortech Systems, Inc. and Subsidiary;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2022	By:	/s/ Jay D. Miller
		Jay D. Miller
		Chief Executive Officer and President
		Nortech Systems Incorporated

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Christopher D. Jones, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Nortech Systems, Inc. and Subsidiary;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2022	By:	/s/ Christopher D. Jones
		Christopher D. Jones
		Vice President and Chief Financial Officer
		Nortech Systems Incorporated

EX-32

Exhibit 32

Written Statement of the Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350

Solely for the purposes of complying with 18 U.S.C. Section 1350, I, the undersigned Jay D. Miller, hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2022

By:	/s/ Jay D. Miller
	Jay D. Miller
	Chief Executive Officer and President
	Nortech Systems Incorporated

Written Statement of the Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350

Solely for the purposes of complying with 18 U.S.C. Section 1350, I, the undersigned Christopher D. Jones, hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2022

By:	/s/ Christopher D. Jones
	Christopher D. Jones
	Vice President and Chief Financial Officer
	Nortech Systems Incorporated

XML

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document Information [Line Items]
Entity Central Index Key	0000722313
Entity Registrant Name	NORTECH SYSTEMS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	0-13257
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1681094
Entity Address, Address Line One	7550 Meridian Circle N., Suite # 150
Entity Address, City or Town	Maple Grove
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55369
City Area Code	952
Local Phone Number	345-2244
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	NSYS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,683,513

XML

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net sales	$ 32,518	$ 30,182	$ 63,229	$ 52,254
Cost of Goods Sold	27,514	26,597	54,181	47,108
Gross Profit	5,004	3,585	9,048	5,146
Operating Expenses
Selling Expenses	960	571	1,793	1,292
General and Administrative Expenses	2,668	2,418	5,397	5,214
Research and Development Expenses	351	207	679	207
Restructuring Charges	0	77	0	296
Gain on Sale of Assets	0	(94)	(15)	(94)
Total Operating Expenses	3,979	3,179	7,854	6,915
Income (Loss) From Operations	1,025	406	1,194	(1,769)
Other Expense
Interest Expense	(117)	(116)	(215)	(202)
Income (Loss) Before Income Taxes	908	290	979	(1,971)
Income Tax Expense (Benefit)	189	111	122	(596)
Net Income (Loss)	$ 719	$ 179	$ 857	$ (1,375)
Net Income (Loss) Per Common Share:
Basic (in dollars per share) (in dollars per share)	$ 0.27	$ 0.07	$ 0.32	$ (0.52)
Weighted Average Number of Common Shares Outstanding - Basic (in shares) (in shares)	2,683,131	2,658,926	2,681,931	2,659,028
Diluted (in dollars per share) (in dollars per share)	$ 0.25	$ 0.06	$ 0.30	$ (0.52)
Weighted Average Number of Common Shares Outstanding - Diluted (in shares) (in shares)	2,886,755	2,767,991	2,879,216	2,659,028
Other comprehensive (loss) income
Foreign currency translation	$ (244)	$ 58	$ (239)	$ 24
Comprehensive income (loss), net of tax	$ 475	$ 237	$ 618	$ (1,351)

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 944	$ 643
Restricted Cash	231	1,582
Accounts Receivable, less allowances of $297 and $328	16,468	14,548
Employee Retention Credit Receivable	5,209	5,209
Inventories, Net	22,970	19,434
Contract Assets	9,070	8,698
Prepaid Expenses and Other Current Assets	1,563	1,660
Total Current Assets	56,455	51,774
Property and Equipment, Net	6,144	5,833
Operating Lease Assets	8,420	8,983
Other Intangible Assets, Net	471	501
Total Assets	71,490	67,091
Current Liabilities
Current Portion of Finance Lease Obligations	447	601
Current Portion of Operating Lease Obligations	1,099	1,043
Accounts Payable	14,108	12,710
Accrued Payroll and Commissions	3,961	4,045
Other Accrued Liabilities	4,675	3,907
Total Current Liabilities	24,290	22,306
Long-Term Liabilities
Long Term Line of Credit	11,360	8,959
Long Term Finance Lease Obligations, Net	734	916
Long-Term Operating Lease Obligations, Net	8,103	8,695
Other Long-Term Liabilities	100	104
Total Long-Term Liabilities	20,297	18,674
Total Liabilities	44,587	40,980
Commitments and Contingencies
Shareholders' Equity
Preferred Stock, $1 par value; 1,000,000 Shares Authorized: 250,000 Shares Issued and Outstanding	250	250
Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,683,513 and 2,672,064 Shares Issued and Outstanding, respectively	27	27
Additional Paid-In Capital	16,136	15,962
Accumulated Other Comprehensive (Income) Loss	(183)	56
Retained Earnings	10,673	9,816
Total Shareholders' Equity	26,903	26,111
Total Liabilities and Shareholders' Equity	$ 71,490	$ 67,091

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts receivable allowance	$ 297	$ 328
Preferred stock, par value (in dollars per share)	$ 1	$ 1
Preferred Stock, Shares Authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	250,000	250,000
Preferred stock, shares outstanding (in shares)	250,000	250,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	9,000,000	9,000,000
Common stock, shares issued (in shares)	2,683,513	2,672,064
Common stock, shares outstanding (in shares)	2,683,513	2,672,064

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ 857	$ (1,375)
Adjustments to Reconcile Net Income (Loss) to Net Cash
Depreciation and Amortization	967	967
Compensation on Stock-Based Awards	141	160
Change in Accounts Receivable Allowance	(31)	116
Change in Inventory Reserves	(103)	(655)
Gain on Sale of Assets	(15)	(94)
Changes in Current Operating Items
Accounts Receivable	(1,986)	(1,153)
Inventories	(3,540)	(3,719)
Contract Assets	(372)	(1,019)
Prepaid Expenses and other Curent Assets	89	(286)
Income Taxes	(63)	(757)
Accounts Payable	1,346	1,576
Accrued Payroll and Commissions	(84)	686
Other Accrued Liabilities	854	120
Net Cash Used In Operating Activities	(1,940)	(5,433)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from Sale of Property and Equipment	15	94
Purchase of Intangible Asset	(41)	(77)
Purchases of Property and Equipment	(1,182)	(659)
Net Cash Used In Investing Activities	(1,208)	(642)
CASH FLOWS FROM FINANCING ACTIVITIES
Net Change in Line of Credit	2,394	4,339
Principal Payments on Long-Term Debt	0	(249)
Principal Payments on Financing Leases	(336)	(326)
Debt Issuance Costs	7	0
Stock Option Excercises	33	0
Net Cash Provided By Financing Activities	2,098	3,764
Net Change in Cash and Cash Equivalents	(1,050)	(2,311)
Cash and Cash Equivalents - Beginning of Period	2,225	3,564
Cash and Cash Equivalents - End of Period	1,175	1,253
Reconciliation of cash and restricted cash reported within the consolidated balance sheets
Cash	944	661
Restricted Cash	231	592
Total Cash and restricted cash reported in the consolidated statements of cash flows	1,175	1,253
Supplemental Disclosure of Cash Flow Information:
Cash Paid During the Period for Interest	198	81
Cash Paid During the Period for Income Taxes	20	156
Supplemental Noncash Investing and Financing Activities:
Property and Equipment Purchases in Accounts Payable	52	0
Right-of-use assets obtained in exchange for lease obligations	$ 0	$ 858

XML

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
BALANCE at Dec. 31, 2020	$ 250	$ 27	$ 15,816	$ (37)	$ 2,662	$ 18,718
Net Income (Loss)	0	0	0	0	(1,375)	(1,375)
Foreign currency translation adjustment	0	0	0	24	0	24
Compensation on stock-based awards	0	0	46	0	0	46
BALANCE at Jun. 30, 2021	250	27	15,862	(13)	1,287	17,413
BALANCE at Mar. 31, 2021	250	27	15,837	(71)	1,108	17,151
Net Income (Loss)	0	0	0	0	179	179
Foreign currency translation adjustment	0	0	0	58	0	58
Compensation on stock-based awards	0	0	25	0	0	25
BALANCE at Jun. 30, 2021	250	27	15,862	(13)	1,287	17,413
BALANCE at Dec. 31, 2021	250	27	15,962	56	9,816	26,111
Net Income (Loss)	0	0	0	0	857	857
Foreign currency translation adjustment	0	0	0	(239)	0	(239)
Compensation on stock-based awards	0	0	141	0	0	141
Stock option exercises	0	0	33	0	0	33
BALANCE at Jun. 30, 2022	250	27	16,136	(183)	10,673	26,903
BALANCE at Mar. 31, 2022	250	27	16,043	61	9,954	26,335
Net Income (Loss)	0	0	0	0	719	719
Foreign currency translation adjustment	0	0	0	(244)	0	(244)
Compensation on stock-based awards	0	0	93	0	0	93
BALANCE at Jun. 30, 2022	$ 250	$ 27	$ 16,136	$ (183)	$ 10,673	$ 26,903

XML

Note 1 - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

NOTE 1.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements, although we believe the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other interim period. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these condensed consolidated financial statements, we have made our best estimates and judgments of certain amounts included in the condensed consolidated financial statements, giving due consideration to materiality. Changes in the estimates and assumptions used by us could have a significant impact on our financial results, since actual results could differ from those estimates.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Revenue Recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation. Revenue is recorded net of returns, allowances and customer discounts. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs charged to our customers are included in net sales, while the corresponding shipping expenses are included in cost of goods sold.

Stock-Based Awards

Stock Options

In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of 350,000 shares. An additional 50,000 and 175,000 shares were authorized by the shareholders in March 2020 and May 2022, respectively.

We granted 0 and 21,000 market condition options to our Chief Executive Officer during the three and six months ended June 30, 2022, respectively. The market condition options vest if certain stock prices are exceeded between February 27, 2024 and February 27, 2028. We granted 13,000 and 66,000 service-based options during the three and six months ended June 30, 2022, respectively. Total option grants for the three and six months ended June 30, 2022 were 13,000 and 108,000, respectively. There were 3,000 stock options granted during the six months ended June 30, 2021.

Total compensation expense related to stock options was $64 and $106 for the three and six months ended June 30, 2022, respectively. Total compensation expense related to stock options was $25 and $46 for the three and six months ended June 30, 2021. As of June 30, 2022, there was $851 of unrecognized compensation which will vest over the next 3.90 years.

Following is the status of all stock options as of June 30, 2022:

	Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding - January 1, 2022		387,500		$	4.57
Granted		87,000			11.10
Exercised		(12,000	)		3.41
Cancelled		(4,400	)		3.36
Outstanding - June 30, 2022		458,100		$	5.82		6.97	$	3,326
Exercisable - June 30, 2022		222,700		$	3.93		6.12	$	2,038

Restricted Stock Units

During the three and six months ended June 30, 2022, we granted 3,000 and 21,000 restricted stock units (“RSUs”), respectively, under our 2017 Stock Incentive Plan to non-employee directors which vest over two years. There were no RSUs outstanding prior to the six months ended June 30, 2022. Total compensation expense related to the RSUs were $29 and $35 for the three and six months ended June 30, 2022, respectively. There was no compensation expense related to RSUs for the three and six months ended June 30, 2021. Total unrecognized compensation expense related to the RSUs was $218, which will vest over the next 1.74 years. The RSUs granted in the six months ended June 30, 2022 had an average grant price of $12.00 per share with a weighted average remaining contractual term of 9.73 years. No RSUs vested during the six months ended June 30, 2022.

Equity Appreciation Rights Plan

In November 2010, the Board of Directors adopted the Nortech Systems Incorporated Equity Appreciation Rights Plan (“2010 Plan”). The total number of Equity Appreciation Right Units (“Units”) that can be issued under the 2010 Plan shall not exceed an aggregate of 1,000,000 Units as amended and restated on March 11, 2015. There were no units granted during the six months ended June 30, 2022 or June 30, 2021.

The 100,000 units outstanding at December 31, 2021 were paid on March 29, 2022. As of June 30, 2022, there are no units outstanding. Total compensation expense related to the vested outstanding Units based on the estimated appreciation over their remaining terms was $100 and $114 for the three and six months ended June 30, 2021, respectively.

Net Income (Loss) per Common Share

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Dilutive net income (loss) per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding, unless their effect is antidilutive. All stock options and restricted stock units, while outstanding, are considered common stock equivalents.

For the three and six months ended June 30, 2022, stock options of 203,625 and 197,285, respectively were included in the computation of diluted net income per common share as their impact were dilutive. For the three months ended June 30, 2021, stock options of 109,065 were included in the computation of diluted net income per common share. For the six months ended June 30, 2021, all stock options are deemed to be antidilutive and therefore, were not included in the computation of net income per common share amount.

We had outstanding stock options totaling 45,878 and RSUs totaling 19,114 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the three months ended June 30, 2022. We had average outstanding stock options totaling 48,895 and RSUs totaling 20,057 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the six months ended June 30, 2022. Outstanding stock options totaling 622 are not considered in the computation of diluted net income per share for the three months ended June 30, 2021.

Restricted Cash

Cash and cash equivalents classified as restricted cash on our consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. As of June 30, 2022 we had outstanding letters of credit for $400. Restricted cash as of June 30, 2022 was $231. The June 30, 2022 restricted cash balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

Accounts Receivable and Allowance for Doubtful Accounts

Credit is extended based upon an evaluation of the customer’s financial condition and, while collateral is not required, the Company periodically receives surety bonds that guarantee payment. Credit terms are consistent with industry standards and practices. Trade accounts receivable have been reduced by an allowance for doubtful accounts of $297 at June 30, 2022 and $328 at December 31, 2021.

Inventories

Inventories are stated at the lower of average cost (which approximates first-in, first out) or net realizable value. Costs include material, labor, and overhead required in the warehousing and production of our products. Inventory reserves are maintained for the estimated value of the inventories that may have a lower value than stated or quantities in excess of future production needs.

Inventories are as follows:

	June 30,			December 31,
	2022			2021
Raw Materials	$	21,764		$	18,492
Work in Process		1,793			1,678
Finished Goods		608			562
Reserves		(1,195	)		(1,298	)
Total	$	22,970		$	19,434

Other Intangible Assets

Other intangible assets at June 30, 2022 and December 31, 2021 are as follows:

	Customer Relationships		Trade Names		Patents		Total
Balance at January 1, 2021	$	507	$	589	$	77	$	1,173
Additions		-		-		64		64
Amortization		147		29		-		176
Abandonment Loss		-		560		-		560
Balance at December 31, 2021		360		-		141		501
Additions		-		-		41		41
Amortization		71		-		-		71
Balance at June 30, 2022	$	289	$	-	$	182	$	471

Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted-average remaining amortization period of our in-use intangible asset is 2.0 years. Patents are not being amortized as they are in process and a patent has not yet been received.

Amortization expense of finite life intangible assets for the three and six months ended June 30, 2022 was $35 and $71, respectively. Amortization expense for the three and six months ended June 30, 2021 was $46 and $92, respectively.

Estimated future annual amortization expense (not including the patents in process) related to these assets is approximately as follows:

Year	Amount
Remainder of 2022	$	72
2023		145
2024		72
Total	$	289

Accounting Pronouncements Issued But Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The ASU also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities that meet the definition of a Smaller Reporting Company as defined by the SEC for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.

XML

Note 2 - Concentration of Credit Risk and Major Customers

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

NOTE 2.   CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. With regard to cash, we maintain our excess cash balances in checking accounts at primarily two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. Of the $1,175 in cash and restricted cash at June 30, 2022, approximately $691 and $54 was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and do not require collateral on our accounts receivable.

We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances individually represented 10% or more of total accounts receivable. One customer accounted for 28% and 26% of net sales for the three and six months ended June 30, 2022, respectively. One customer accounted for 25% and 27% of net sales for the three and six months ended June 30, 2021, respectively.

At June 30, 2022, two customers represented approximately 37% of our total accounts receivable. At December 31, 2021, one customer represented approximately 19% of our total accounts receivable.

Export sales represented approximately 4% of net sales for both the three and six months ended June 30, 2022. Export sales represented approximately 2% and 3% of net sales for the three and six months ended June 30, 2021 respectively.

XML

Note 3 - Revenue

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

NOTE 3.   REVENUE

Revenue recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct.

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 74% of our revenue for both the three and six months ended June 30, 2022 and 82% and 79% of our revenue for the three and six months ended June 30, 2021, respectively. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred.

Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.

On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.

Contract Assets

Contract assets, recorded as such in the Condensed Consolidated Balance Sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the six months ended June 30, 2022 was as follows (in thousands):

Balance outstanding at December 31, 2021	$	8,698
Increase (decrease) attributed to:
Transferred to receivables from beginning contract assets		(8,360	)
Product transferred over time to ending contract assets		8,732
Balance outstanding at June 30, 2022	$	9,070

We expect substantially all the remaining performance obligations for the contract assets recorded as of June 30, 2022 to be transferred to receivables within 90 days, with the majority of any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

The following tables summarize our net sales by market:

	Three Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	13,165	$	4,763	$	610	$	18,538
Industrial		6,930		2,196		328		9,454
Aerospace and Defense		3,989		336		201		4,526
Total net sales	$	24,084	$	7,295	$	1,139	$	32,518

	Three Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	12,776	$	3,050	$	244	$	16,070
Industrial		8,287		1,738		151		10,176
Aerospace and Defense		3,738		122		76		3,936
Total net sales	$	24,801	$	4,910	$	471	$	30,182

	Six Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	22,972	$	9,678	$	1,154	$	33,804
Industrial		13,459		3,987		675		18,121
Aerospace and Defense		10,046		761		497		11,304
Total net sales	$	46,477	$	14,426	$	2,326	$	63,229

	Six Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	21,735	$	5,942	$	734	$	28,411
Industrial		12,917		3,075		403		16,395
Aerospace and Defense		6,802		384		262		7,448
Total net sales	$	41,454	$	9,401	$	1,399	$	52,254

XML

Note 4 - Financing Arrangements

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Debt Disclosure [Text Block]

NOTE 4.   FINANCING ARRANGEMENTS

We have a credit agreement with Bank of America which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16,000 that expires on June 15, 2026.

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 3.9% and 3.5% as of June 30, 2022 and December 31, 2021, respectively. We had borrowings on our line of credit of $11,410 and $9,016 outstanding as of June 30, 2022 and December 31, 2021, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $50 and $58 on the consolidated balance sheet for the periods ended June 30, 2022 and December 31, 2021, respectively.

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0 for the twelve months ended at each Fiscal Quarter end subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 days. As of June 30, 2022 the Company was in compliance with its covenants.

At June 30, 2022, we had unused availability under our line of credit of $4,190 supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability.

XML

Note 5 - Leases

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Lease Disclosure [Text Block]

NOTE 5.   LEASES

We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. At June 30, 2022, we do not have material lease commitments that have not commenced.

The components of lease expense were as follows:

	Three Months Ended June 30,		Three Months Ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	578	$	589
Finance lease interest cost		17		21
Finance lease amortization expense		183		163
Total lease cost	$	778	$	773

	Six Months Ended June 30,		Six Months ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	1,159	$	1,120
Finance lease interest cost		36		43
Finance lease amortization expense		365		326
Total lease cost	$	1,560	$	1,489

Supplemental balance sheet information related to leases was as follows:

	Balance Sheet Location	June 30, 2022		December 31, 2021
Assets
Operating lease assets	Operating lease assets	$	8,420	$	8,983
Finance lease assets	Property, plant and equipment		1,867		2,052
Total leased assets		$	10,287	$	11,035

Supplemental cash flow information related to leases was as follows:

	June 30,		June 30,
	2022		2021
Operating leases
Cash paid for amounts included in the measurement of lease liabilities	$	862	$	821
Right-of-use assets obtained in exchange for lease obligations	$	-	$	858

Maturities of lease liabilities were as follows:

	Operating Leases			Finance Leases			Total
Remaining 2022	$	871		$	293		$	1,164
2023		1,789			409			2,198
2024		1,507			357			1,864
2025		1,255			103			1,358
2026		1,217			115			1,332
Thereafter		7,066			-			7,066
Total lease payments	$	13,705		$	1,277		$	14,982
Less: Interest		(4,504	)		(96	)		(4,600	)
Present value of lease liabilities	$	9,201		$	1,181		$	10,382

The lease term and discount rate at June 30, 2022 were as follows:

Weighted-average remaining lease term (years)
Operating leases	9.2
Finance leases	2.6
Weighted-average discount rate
Operating leases	7.7	%
Finance leases	5.2	%

XML

Note 6 - Income Taxes

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE 6.   INCOME TAXES

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction.

Our effective tax rate for the three and six months ended June 30, 2022 was 21% and 12%, respectively. The effective tax rate for the three and six months ended June 30, 2021 was 38% and 30%, respectively. The primary driver of the change in the effective tax rate is attributable to a US loss compared to income from the foreign entities.

XML

Note 7 - Restructuring Charges

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

NOTE 7.   RESTRUCTURING CHARGES

During the first six months of 2021, we recorded restructuring charges of $296 related to the consolidation of our production facilities and closure of our Merrifield, Minnesota facility. We had a gain on sale of assets of $15 and $94 in the six months ended June 30, 2022 and 2021, respectively, related to the sale of machinery and equipment. There were no restructuring charges or amounts accrued in the six months ended June 30, 2022.

XML

Note 8 - Employee Retention Credit

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Employee Retention Credit [Text Block]

NOTE 8.   EMPLOYEE RETENTION CREDIT

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law providing numerous tax provisions and other stimulus measures, including an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERC.

At June 30, 2022 and December 31, 2021, the Company has ERC benefits of $5,209 within Employee Retention Credits Receivable on the condensed consolidated balance sheet.

XML

Note 9 - Related Party Transactions

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

NOTE 9.   RELATED PARTY TRANSACTIONS

David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. Mr. Kunin also was a consultant to Abilitech, which relationship ended on March 1, 2021. In the three and six months ended June 30, 2022, Abilitech paid the Company $163 and $217, respectively, for delivery of medical products. In the three and six months ended June 30, 2021, Abilitech paid the Company $472 and $740, respectively for the delivery of medical products. The Company believes that transactions with Abilitech are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated third party.

David Kunin, our Chairman, is a minority owner (less than 10%) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $1,000 conditional grant. The Company and Marpe Technologies will each receive $500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $500 to match grant funds from the BIRD Foundation. The Company will meet its obligation by providing certain services at cost or no cost to Marpe Technologies. The total value of the contribution will not exceed $500; the Company has contributed $182 as of June 30, 2022. The Company will receive a 10-year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recoup the value of services provided to Marpe for which is not fully paid. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the six months ended June 30, 2022, we recognized revenue of $113. There was no revenue recognized for the six months ended June 30, 2021. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party.

XML

Note 1 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding - January 1, 2022		387,500		$	4.57
Granted		87,000			11.10
Exercised		(12,000	)		3.41
Cancelled		(4,400	)		3.36
Outstanding - June 30, 2022		458,100		$	5.82		6.97	$	3,326
Exercisable - June 30, 2022		222,700		$	3.93		6.12	$	2,038

Schedule of Inventory, Current [Table Text Block]

	June 30,			December 31,
	2022			2021
Raw Materials	$	21,764		$	18,492
Work in Process		1,793			1,678
Finished Goods		608			562
Reserves		(1,195	)		(1,298	)
Total	$	22,970		$	19,434

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	Customer Relationships		Trade Names		Patents		Total
Balance at January 1, 2021	$	507	$	589	$	77	$	1,173
Additions		-		-		64		64
Amortization		147		29		-		176
Abandonment Loss		-		560		-		560
Balance at December 31, 2021		360		-		141		501
Additions		-		-		41		41
Amortization		71		-		-		71
Balance at June 30, 2022	$	289	$	-	$	182	$	471

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year	Amount
Remainder of 2022	$	72
2023		145
2024		72
Total	$	289

XML

Note 3 - Revenue (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Balance outstanding at December 31, 2021	$	8,698
Increase (decrease) attributed to:
Transferred to receivables from beginning contract assets		(8,360	)
Product transferred over time to ending contract assets		8,732
Balance outstanding at June 30, 2022	$	9,070

Disaggregation of Revenue [Table Text Block]

	Three Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	13,165	$	4,763	$	610	$	18,538
Industrial		6,930		2,196		328		9,454
Aerospace and Defense		3,989		336		201		4,526
Total net sales	$	24,084	$	7,295	$	1,139	$	32,518

	Three Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	12,776	$	3,050	$	244	$	16,070
Industrial		8,287		1,738		151		10,176
Aerospace and Defense		3,738		122		76		3,936
Total net sales	$	24,801	$	4,910	$	471	$	30,182

	Six Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	22,972	$	9,678	$	1,154	$	33,804
Industrial		13,459		3,987		675		18,121
Aerospace and Defense		10,046		761		497		11,304
Total net sales	$	46,477	$	14,426	$	2,326	$	63,229

	Six Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	21,735	$	5,942	$	734	$	28,411
Industrial		12,917		3,075		403		16,395
Aerospace and Defense		6,802		384		262		7,448
Total net sales	$	41,454	$	9,401	$	1,399	$	52,254

XML

Note 5 - Leases (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Lease, Cost [Table Text Block]

	Three Months Ended June 30,		Three Months Ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	578	$	589
Finance lease interest cost		17		21
Finance lease amortization expense		183		163
Total lease cost	$	778	$	773

	Six Months Ended June 30,		Six Months ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	1,159	$	1,120
Finance lease interest cost		36		43
Finance lease amortization expense		365		326
Total lease cost	$	1,560	$	1,489

	June 30,		June 30,
	2022		2021
Operating leases
Cash paid for amounts included in the measurement of lease liabilities	$	862	$	821
Right-of-use assets obtained in exchange for lease obligations	$	-	$	858

Weighted-average remaining lease term (years)
Operating leases	9.2
Finance leases	2.6
Weighted-average discount rate
Operating leases	7.7	%
Finance leases	5.2	%

Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]

	Balance Sheet Location	June 30, 2022		December 31, 2021
Assets
Operating lease assets	Operating lease assets	$	8,420	$	8,983
Finance lease assets	Property, plant and equipment		1,867		2,052
Total leased assets		$	10,287	$	11,035

Schedule of Lease Liability Maturity [Table Text Block]

	Operating Leases			Finance Leases			Total
Remaining 2022	$	871		$	293		$	1,164
2023		1,789			409			2,198
2024		1,507			357			1,864
2025		1,255			103			1,358
2026		1,217			115			1,332
Thereafter		7,066			-			7,066
Total lease payments	$	13,705		$	1,277		$	14,982
Less: Interest		(4,504	)		(96	)		(4,600	)
Present value of lease liabilities	$	9,201		$	1,181		$	10,382

XML

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2022	Mar. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	May 31, 2017	Dec. 31, 2012	Nov. 30, 2010
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					87,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 11.10
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)					6 years 11 months 19 days
Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total (in shares)			203,625	109,065	197,285
Letters of Credit Outstanding, Amount			$ 400		$ 400
Restricted Cash and Cash Equivalents, Current, Total			231	$ 592	231	$ 592	$ 1,582
Accounts Receivable, Allowance for Credit Loss, Current			297		$ 297		328
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)					2 years
Amortization of Intangible Assets			$ 35	46	$ 71	$ 92	$ 176
Employee Market Condition Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			0		21,000
Employee Service-based Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			13,000		66,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			13,000		108,000	3,000
Share-Based Payment Arrangement, Expense			$ 64	$ 25	$ 106	$ 46
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 851		$ 851
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					3 years 10 months 24 days
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			45,878	622	48,895
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			19,114		20,057
Stock Appreciation Rights (SARs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)			0		0				100,000
Equity Appreciation Right Units [Member]
Share-Based Payment Arrangement, Expense				$ 100		$ 114
Stock Incentive Plan 2017 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)								350,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	175,000	50,000
Stock Incentive Plan 2017 [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expense			$ 29	$ 0	$ 35	$ 0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 218		$ 218
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 8 months 26 days
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 12.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)					9 years 8 months 23 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value					$ 0
Stock Incentive Plan 2017 [Member] | Restricted Stock Units (RSUs) [Member] | Non-employee Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			3,000		21,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					2 years
Equity Appreciation Rights Plan 2010 [Member] | Stock Appreciation Rights (SARs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)										1,000,000

XML

Note 1 - Summary of Significant Accounting Policies - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022
Outstanding (in shares)	387,500
Outstanding, weighted average exercise price (in dollars per share)	$ 4.57
Granted (in shares)	87,000
Granted, weighted average exercise price (in dollars per share)	$ 11.10
Exercised (in shares)	(12,000)
Exercised, weighted average exercise price (in dollars per share)	$ 3.41
Cancelled (in shares)	(4,400)
Cancelled, weighted average exercise price (in dollars per share)	$ 3.36
Outstanding (in shares)	458,100
Outstanding, weighted average exercise price (in dollars per share)	$ 5.82
Outstanding, weighted average remaining contractual term (Year)	6 years 11 months 19 days
Outstanding, aggregate intrinsic value	$ 3,326
Exercisable (in shares)	222,700
Exercisable, weighted average exercise price (in dollars per share)	$ 3.93
Exercisable, weighted average remaining contractual term (Year)	6 years 1 month 13 days
Exercisable, aggregate intrinsic value	$ 2,038

XML

Note 1 - Summary of Significant Accounting Policies - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Raw Materials	$ 21,764	$ 18,492
Work in Process	1,793	1,678
Finished Goods	608	562
Reserves	(1,195)	(1,298)
Total	$ 22,970	$ 19,434

XML

Note 1 - Summary of Significant Accounting Policies - Finite Lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Beginning balance			$ 501	$ 1,173	$ 1,173
Additions			41		64
Amortization	$ (35)	$ (46)	(71)	(92)	(176)
Abandonment Loss					560
Ending balance	471		471		501
Customer Relationships [Member]
Beginning balance			360	507	507
Additions			0		0
Amortization			(71)		(147)
Abandonment Loss					0
Ending balance	289		289		360
Trade Names [Member]
Beginning balance			0	589	589
Additions			0		0
Amortization			0		(29)
Abandonment Loss					560
Ending balance	0		0		0
Patents [Member]
Beginning balance			141	$ 77	77
Additions			41		64
Amortization			0		0
Abandonment Loss					0
Ending balance	$ 182		$ 182		$ 141

XML

Note 1 - Summary of Significant Accounting Policies - Estimated Future Annual Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Total	$ 471	$ 501	$ 1,173
Finite-lived Intangible Assets, Excluding Projects in Process [Member]
Remainder of 2022	72
2023	145
2024	72
Total	$ 289

XML

Note 2 - Concentration of Credit Risk and Major Customers (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021	Jun. 30, 2022 USD ($)	Jun. 30, 2021	Dec. 31, 2021
Excess Cash Balances, Number of High Credit Quality Financial Institutions			2
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage	28.00%	25.00%	26.00%	27.00%
Concentration Risk Number of Customers	1	1	1	1
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | Largest Customer [Member]
Concentration Risk, Percentage	4.00%	2.00%	4.00%	3.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage			37.00%		19.00%
Concentration Risk Number of Customers			2		1
UNITED STATES
Excess Cash Balances, Number of High Credit Quality Financial Institutions			1,000
Cash	$ 1,175		$ 1,175
CHINA
Excess Cash Balances, Number of High Credit Quality Financial Institutions			1
Cash	691		$ 691
MEXICO
Cash	$ 54		$ 54

XML

Note 3 - Revenue 1 (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Percentage of Revenue Transferred to Customers	74.00%	82.00%	74.00%	79.00%
Revenue Remaining Performance Obligation, Customers Upon Shipment With Payment Terms (Day)			120 days

XML

Note 3 - Revenue 2 (Details Textual)	Jun. 30, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Day)	180 days

XML

Note 3 - Revenue - Contract Assets (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Balance outstanding at December 31, 2021	$ 8,698
Transferred to receivables from beginning contract assets	(8,360)
Product transferred over time to ending contract assets	8,732
Balance outstanding at June 30, 2022	$ 9,070

XML

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net sales	$ 32,518	$ 30,182	$ 63,229	$ 52,254
Medical [Member]
Net sales	18,538	16,070	33,804	28,411
Industrial [Member]
Net sales	9,454	10,176	18,121	16,395
Aerospace and Defense [Member]
Net sales	4,526	3,936	11,304	7,448
Transferred over Time [Member]
Net sales	24,084	24,801	46,477	41,454
Transferred over Time [Member] | Medical [Member]
Net sales	13,165	12,776	22,972	21,735
Transferred over Time [Member] | Industrial [Member]
Net sales	6,930	8,287	13,459	12,917
Transferred over Time [Member] | Aerospace and Defense [Member]
Net sales	3,989	3,738	10,046	6,802
Transferred at Point in Time [Member]
Net sales	7,295	4,910	14,426	9,401
Transferred at Point in Time [Member] | Medical [Member]
Net sales	4,763	3,050	9,678	5,942
Transferred at Point in Time [Member] | Industrial [Member]
Net sales	2,196	1,738	3,987	3,075
Transferred at Point in Time [Member] | Aerospace and Defense [Member]
Net sales	336	122	761	384
Noncash Consideration [Member]
Net sales	1,139	471	2,326	1,399
Noncash Consideration [Member] | Medical [Member]
Net sales	610	244	1,154	734
Noncash Consideration [Member] | Industrial [Member]
Net sales	328	151	675	403
Noncash Consideration [Member] | Aerospace and Defense [Member]
Net sales	$ 201	$ 76	$ 497	$ 262

XML

Note 4 - Financing Arrangements (Details Textual) - Credit Agreement [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 15, 2017 USD ($)
Bank of America [Member]
Debt Issuance Costs, Net, Total	$ 50,000	$ 58,000
Bank of America [Member]
Long-Term Line of Credit, Total	$ 11,410,000	$ 9,016,000
Line of Credit, Minimum Fixed Charge Coverage Ratio During the Period	1.0
Line of Credit Facility, Remaining Borrowing Capacity	$ 4,190
Bank of America [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 16,000,000
Debt Instrument, Interest Rate During Period	3.90%	3.50%

XML

Note 5 - Leases (Details Textual)	Jun. 30, 2022
Minimum [Member]
Lessee, Operating Lease, Renewal Term (Year)	1 year
Maximum [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years

XML

Note 5 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating lease cost	$ 578	$ 589	$ 1,159	$ 1,120
Finance lease interest cost	17	21	36	43
Finance lease amortization expense	183	163	365	326
Total lease cost	$ 778	$ 773	1,560	1,489
Cash paid for amounts included in the measurement of lease liabilities			862	821
Right-of-use assets obtained in exchange for lease obligations			$ 0	$ 858
Operating leases (Year)	9 years 2 months 12 days		9 years 2 months 12 days
Finance leases (Year)	2 years 7 months 6 days		2 years 7 months 6 days
Operating leases	7.70%		7.70%
Finance leases	5.20%		5.20%

XML

Note 5 - Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating lease assets	$ 8,420	$ 8,983
Total leased assets	10,287	11,035
Property and Equipment [Member]
Finance lease assets	$ 1,867	$ 2,052

XML

Note 5 - Leases - Maturity of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Operating leases, Remaining 2022	$ 871
Finance leases, Remaining 2022	293
Total, Remaining 2022	1,164
Operating leases, 2023	1,789
Finance leases, 2023	409
Total, 2023	2,198
Operating leases, 2024	1,507
Finance leases, 2024	357
Total, 2024	1,864
Operating leases, 2025	1,255
Finance leases, 2025	103
Total, 2025	1,358
Operating leases, 2026	1,217
Finance leases, 2026	115
Total, 2026	1,332
Operating leases, Thereafter	7,066
Finance leases, Thereafter	0
Total, Thereafter	7,066
Operating leases, total lease payments	13,705
Finance leases, total lease payments	1,277
Total, total lease payments	14,982
Operating leases, less: Interest	(4,504)
Finance leases, less: Interest	(96)
Total, less: Interest	(4,600)
Operating leases, present value of lease liabilities	9,201
Finance leases, present value of lease liabilities	1,181
Total, present value of lease liabilities	$ 10,382

XML

Note 6 - Income Taxes (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Effective Income Tax Rate Reconciliation, Percent, Total	21.00%	38.00%	12.00%	30.00%

XML

Note 7 - Restructuring Charges (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring Charges, Total	$ 0	$ 77	$ 0	$ 296
Consolidation of our Production Facilities and Closure of our Merrifield, Minnesota Facility [Member]
Restructuring Charges, Total				296
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			15	$ 94
Restructuring Reserve, Ending Balance	$ 0		$ 0

XML

Note 8 - Employee Retention Credit (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Employee Retention Credit Benefits, CARES Act	$ 5,209	$ 5,209

XML

Note 9 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Agreement Between the BIRD Foundation, the Company, and MARPE Technologies, LTD [Member]
Agreement, Conditional Grant	$ 1,000		$ 1,000
Agreement, Exclusive Manufacturing Rights, Term (Year)			10 years
Abilitech Medical, Inc [Member] | Payments Received for Delivery of EMS Products [Member]
Related Party Transaction, Amounts of Transaction	$ 163	$ 472	$ 217	$ 740
David Kunin [Member] | Marpe Technologies, LTD [Member] | Maximum [Member]
Ownership, Percent	10.00%		10.00%
Marpe Technologies, LTD [Member] | Agreement Between the BIRD Foundation, the Company, and MARPE Technologies, LTD [Member]
Agreement, Conditional Grant Matching Amount	$ 500		$ 500
Agreement, Contribution Amount	$ 182		182
Revenue from Related Parties			$ 113	$ 0